SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on SELLASs Phase 3 REGAL topline results for GPS, with managements stated November timeline intensifying focus on the final analysis. Traders are split between optimistic expectations and short-squeeze speculation versus concerns about the binary outcome, delays, and recent share-price weakness.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention after quarterly results and an upbeat revenue outlook, with traders highlighting cloud growth and a reported Microsoft deal. Bulls emphasize the raised guidance and AI demand, while skeptics point to widening losses, heavy spending, and whether growth justifies the valuation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel pushed its planned prostate-cancer BLA filing to mid-2027 amid assay-refinement work and ongoing FDA discussions, prompting a sharp selloff and concerns about management credibility and possible dilution. Some traders view it as a CMC delay rather than a rejection, arguing that the Phase 3 results remain unchanged.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos quarterly earnings beat and raised full-year outlook, including stronger AI infrastructure expectations, are driving attention. Traders are split between optimism about networking demand and frustration that the stocks reaction has been muted and volatile, with some questioning margins and whether AI orders will translate into sustained revenue.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Anthropics Claude Sheets and other workplace tools are fueling concern that competition could pressure Microsoft 365 and Copilot, with traders linking the launch to weakness in MSFT shares. The debate is whether new AI tools can displace deeply embedded enterprise software or pose only a limited threat to Microsofts established workflows.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

A disappointing third-quarter report, softer sequential ANKTIVA sales, and concerns about cash burn, possible dilution, and limited management guidance are driving the selloff discussion. Some traders view the reaction as excessive and point to the positive BCG-nave trial result and potential expansion, while others question commercial execution and the funding outlook.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is drawing attention after its Q3 earnings report, with traders weighing strong revenue and profit growth and improving efficiency against concerns about rising delinquencies, credit quality, and whether the results met expectations. Reactions are split, with some viewing the selloff despite solid results as an overreaction and others seeing weaker credit metrics and muted stock performance as reasons for caution.

Cardinal Infrastructure Group, Inc. provides infrastructure services to the residential, commercial, industrial, municipal, and state infrastructure markets. It delivers wet utility installations of water, sewer, and stormwater systems, as well as grading, site clearing, erosion control, drilling and blasting, paving, and other related site services. The company was founded on June 12, 2025 and is headquartered in Raleigh, NC.

Cardinal Infrastructure Group Inc - Ordinary Shares - Class A

A sharp selloff followed Cardinals weak quarterly results, withdrawn full-year guidance and disclosure that its CFO plans to leave, with traders focused on worsening project margins and managements execution. The community is split between concerns about further deterioration and bankruptcy risk, and hopes that the stock is oversold and the authorized buyback could support a recovery; the authorization does not confirm that repurchases have begun.

Modine Manufacturing Co. engages in the provision of thermal management products and solutions. It operates through the Climate Solutions and Performance Technologies business segments. The Climate Solutions segment provides climate-controlled solutions and components, heat transfer products, heating, ventilating, air conditioning and refrigeration products, and data center cooling solutions. The Performance Technologies segment designs and manufactures air- and liquid-cooled technology for vehicular, stationary power, and industrial applications. In addition, the Performance Technologies segment provides thermal solutions to zero-emission and hybrid commercial vehicle and automotive customers, and coating products and application services. The company was founded by Arthur B. Modine on June 23, 1916 and is headquartered in Racine, WI.

Modine Manufacturing Co.

Traders are reacting to a report that Samsung is in discussions to acquire Modine, with speculation about a potential buyout premium driving excitement and debate over the offer price. The acquisition remains unconfirmed in the discussion.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials quarterly results topped expectations and its next-quarter outlook was stronger than consensus, but the shares barely responded and sold off. Traders are debating whether the good news was already priced in, with some questioning how strong the guidance looks after adjusting for an extra week in the quarter; others point to options volatility and broader weakness in chip stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?

SELLASs Phase 3 REGAL trial of GPS in AML has reached its final-analysis milestone, and management has guided to preliminary topline results in November, making the pending readout the main focus. Bulls anticipate strong results and a possible short squeeze, while skeptics emphasize that the outcome is still unknown and warn of downside if the data disappoint; claims of a leak or certain success remain speculation.

CAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge? 

Equity

Sellas director Katherine Bach Kalin's purchased shares would be worth nearly $534,000 if retained, representing a 430% paper gain.

SLS Stock Rises After-Hours: State Street Reveals Over 5% Stake — And One Fund Manager Boosted Holdings By Nearly 1,000% 

Victory Capital increased its holdings 982% to 231,562 shares, nearly eleven times its previous position.

SLS Stock Rises Overnight: Retail Bets The Regal Wait Is Almost Over — Here’s What Wall Street Expects From Earnings 

Analysts expect no revenue and a $0.05 loss per share, versus a $0.07 loss a year earlier.

Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA — Geode Adds More 

Geode’s largest ownership stake was in Sellas at 3%, followed by Iovance at 2% and ImmunityBio at 1%.

SLS Stock Rises Overnight Despite Citi’s 64% Stake Cut — Retail Bulls Say SLS009 Alone Could Outvalue Sellas 

Prospera increased its stake nearly 70%, while Eversource trimmed its position 42% and Nemes Rush held steady.

Sellas To Present SLS009 Data At American Society of Hematology – Initial Results Of Therapy In Newly Diagnosed AML Patients Expected In Q4 

The Phase 2 study evaluated SLS009 alongside Azacitidine and Venetoclax in 62 patients with AML.


SLS Stock Snaps 4-Day Slide As Retail Eyes ASH Abstracts — Fresh Filings Reveal Bigger Swiss, Arizona Pension Bets 

ASH will release regular meeting abstracts on Wednesday, followed by late-breaking abstracts on Dec.7.

SLS Stock Hits Over 1-Month Low: Retail Bulls Double Down Before Cancer Data — Fresh Filings Show Q3 Stake Hikes Of Over 400% 

Kestra raised its stake by 256% and Principal Financial by 61%, while Commonwealth and Cambridge trimmed holdings.

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus 

AstraZeneca emphasized ADC combinations, cell therapies and internally developed cancer vaccines as key oncology priorities.

SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3

Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.

Bullish Sentiment

<ul class="summary-bullets"><li>ImmunityBio insiders led with $9.51 million in sales, including $4.41 million from director Barry Simon.</li><li>Capricor insiders sold $8.37 million in shares, retaining $7.30 million before taxes and fees after option costs.</li><li>All six sellers at ImmunityBio and Capricor used prearranged Rule 10b5-1 trading plans.</li></ul>Investors watching Capricor, ImmunityBio, Sellas and Iovance have more than drug milestones to consider. Insiders at two companies collected nearly $18 million from share sales, while one director bought before the stock rose more than fivefold.<a href="https://stocktwits.com/symbol/IBRX">ImmunityBio</a> insiders collected the most from share sales over the past year, while&nbsp;<a href="https://stocktwits.com/symbol/CAPR">Capricor’s</a> sellers received prices well above where the stock later traded.&nbsp;<a href="https://stocktwits.com/symbol/SLS">Sellas</a> director Katherine Bach Kalin stood out as the only open-market buyer across the four companies. Meanwhile,&nbsp;<a href="https://stocktwits.com/symbol/IOVA">Iovance</a> insiders stayed on the sidelines, reporting no open-market trades, according to data compiled by Fiscal AI.&nbsp;<h2 class="st-heading-2">IBRX Directors Cash In Under Trading Plans</h2>Barry Simon, a director at ImmunityBio, collected $4.41 million from share sales — the most of any insider across the four companies. He and fellow directors Cheryl Cohen and Christobel Selecky sold a combined 1.04 million shares for $9.51 million. Simon’s last sale, of 25,000 shares on Oct.5, trimmed less than 1% of his direct holdings, leaving him with nearly 2.78 million shares.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://thaler.sh/s/IBRX/insiders?utm_source=chatgpt.com">&nbsp;</a>Cohen’s Oct.2 sale made a bigger dent in her existing stake. She exercised options for 55,979 shares at $2.98 and sold 81,056 shares at $10.50, ending the day with 25,077 fewer shares. Together, her sale and Simon’s October trade brought in $1.12 million.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1326110/000132611026000084/xslF345X06/wk-form4_1791324339.xml?utm_source=chatgpt.com">&nbsp;</a>All three directors sold under prearranged Rule 10b5-1 plans. The October trades came shortly before the FDA expanded Anktiva’s bladder cancer indication on Oct.14. Richard Adcock, ImmunityBio’s CEO, said, “The recent label expansion represents an important opportunity to broaden access to ANKTIVA for a significantly larger patient population.”<h2 class="st-heading-2">CAPR Insiders Turn Options Into Millions</h2>Capricor CFO Anthony Bergmann, general counsel Karen Krasney and director Karimah Es Sabar sold 272,529 shares for $8.37 million between March 31 and June 25. Each of the 13 sales matched an option exercise the same day, keeping their previously held common shares intact. After paying about $1.07 million to exercise the options, they were left with $7.30 million before taxes and fees.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://fundamentalytics.com/stocks/capr/insiders/?utm_source=chatgpt.com">&nbsp;</a>The three adopted their trading plans in December 2025, months before the FDA reopened its Deramiocel review in March. Their selling had ended by July’s unfavorable advisory vote on the therapy’s use for Duchenne-related heart disease. Capricor now awaits a Nov.22 FDA decision on an amended application focused on arm and hand impairment in Duchenne muscular dystrophy patients older than nine.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm?utm_source=chatgpt.com">&nbsp;</a>“As we approach our PDUFA date, we remain confident in the strength of our data,” CEO Linda Marban said.<h2 class="st-heading-2">SLS Director’s Buy Gains 430% Ahead Of REGAL Results</h2>Sellas director Katherine Bach Kalin bought 63,400 shares for about $100,806 on Nov.19, 2025, a week after the company updated investors on its Regal leukemia trial. The purchase more than doubled her direct holdings to 104,400 shares.&nbsp;Nearly a year later, that purchase would have been worth $534,000 as of Wednesday, if she kept the shares. This is 5.3 times what she paid, a paper gain of $433,000, or 430%, ahead of Regal’s final results.The Phase 3 trial reached the 80 deaths required for its final survival analysis last month. It tests whether Galinpepimut-S helps acute myeloid leukemia (AML) patients live longer after a second complete remission, with results expected this quarter. “Reaching the 80th event represents a critical milestone in the REGAL trial,” CEO Angelos Stergiou said.Institutional investors also increased their Sellas exposure. They added a net 18.8 million shares in the quarter ended June 30, lifting ownership to 36%, according to Fiscal AI. Over the same quarter, they cut their Capricor holdings by 1.9 million shares, though they still owned 55% of the company.<h2 class="st-heading-2">IOVA Insiders Stay On The Sidelines</h2>On the other hand, Iovance insiders made no open-market trades over the past year as sales of Amtagvi, its melanoma cell therapy, continued to climb. U.S. sales rose 77% to about $102 million, helping push Q3 product revenue up 80% from a year earlier.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://thaler.sh/s/IOVA/insiders?utm_source=chatgpt.com">&nbsp;</a>“Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand,” interim CEO Frederick Vogt said. The company maintained its 2026 revenue forecast of $410 million to $420 million and is planning a 2027 FDA filing to expand Amtagvi’s use to lung cancer.<h2 class="st-heading-2">How Do Retail Traders Feel About Biotech Stocks?</h2>On Stocktwits, CAPR led with ‘extremely bullish’ sentiment and ‘extremely high’ message volume, followed by IBRX at ‘bullish’ and ‘high,’ while SLS and IOVA drew ‘bearish’ sentiment on ‘normal’ and ‘low’ volume, respectively.&nbsp;One user&nbsp;<a href="https://stocktwits.com/Stringbag/message/668870521">said</a> about CAPR, “I’m bullish about approval but I still see significant risk.”&nbsp;<stembedurl>https://stocktwits.com/Stringbag/message/668870521</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Docpam/message/668872210">said</a>, “A regular communication schedule, such as a quarterly update or periodic shareholder letter, would go a long way toward building confidence.” A separate user&nbsp;<a href="https://stocktwits.com/MrFinkelstein/message/668868712">said</a>, “If REGAL delivers, this could be a COMPANY-DEFINING moment.”&nbsp;<stembedurl>https://stocktwits.com/Docpam/message/668872210</stembedurl>IBRX led the year-to-date gains with a 237% surge, followed by IOVA at 196% and SLS at 123%, while CAPR lagged with a 61% decline.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-ceo-succession-jensen-huang-replacement-ian-buck-colette-kress/cNGzlDDR99m">Elon Musk Says Hiring Jensen Huang Would ‘Be An Honor’ — But Who Could Replace Him At Nvidia?&nbsp;</a>

Representative Image (Photo credit: Getty Images)

Capricor Therapeutics Inc

iShares Biotechnology ETF

Iovance Biotherapeutics Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

$TMDX

$SLS

Which of these trending stocks are you most tempted to buy - $ON, $TMDX, $SLS, or $BE?

Current Price	$8.03
Prev Close	$8.42
Open	$8.16
Dividend Yield	0.00%
50-Day Moving Average	$11.27
Beta	1.07
Avg. Volume	6.59M
PE Ratio	-39.68

52-Week High	$15.88
52-Week Low	$1.39
Market Capitalization	$1.7B
EPS (Annual)	-$0.2463
Price to Book	12.35
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SLS Fundamentals